Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent annotations, the description discloses substantial behavior: the call cascades through multiple lookup endpoints, unresolved identifiers are returned under an `unresolved` field rather than omitted, ambiguous matches assert nothing and return `figi_candidates`, and LEI/FIGI enrichment degrades gracefully when upstream services are unavailable. This gives the agent a reliable mental model of execution behavior.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but almost every clause adds necessary nuance for a complex multi-source resolver. It is front-loaded with examples and the 'Use FIRST' directive, then organized around supported types and edge cases. The heavy parenthetical in the company section is dense but earns its place; a slightly tighter structure would be ideal.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema and two heterogeneous entity types, the description is remarkably complete. It covers input canonicalization, source attribution, unresolved-identifier behavior, ambiguous-match handling, cross-entity ISIN mapping, non-US issuer coverage, and failure degradation. An agent has enough information to decide when to call it and what to expect back.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description adds significant meaning beyond the schema's terse type/value fields. It enumerates accepted input formats (ticker, CIK, ISIN, name; brand or generic drug name), provides explicit examples like 'CH0038863350' and 'ozempic'/'metformin', and explains how ISINs resolve to legal entities via GLEIF. This strongly compensates for any thinness in the schema itself.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user-phrase examples ('What's the ticker for…' / 'find the CIK for…') and states a specific verb+resource: resolve a user-spoken NAME to canonical/official identifiers other tools require as input. It clearly separates itself from siblings like entity_profile by framing this as the first step whenever a name needs to become an ID, rather than profiling or comparing entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly instructs 'Use FIRST whenever you have a name but need an ID,' which tells the agent when to select this tool over alternatives. It also gives rich selection guidance per type, including the critical negative example that users should pass the issuer name only, never the full noun phrase like 'revenue bonds,' because the FIGI lookup matches instrument names.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation3/5

Many tools are clearly distinct, but the existence of multiple ask_pipeworx variants (standard, beta, grounded) and the overlapping check_risk/lookup_ip tools create meaningful selection ambiguity. Description differentiation helps but doesn't fully resolve it.

Naming Consistency3/5

All names use snake_case, but conventions vary between verb-noun (lookup_ip, compare_entities), noun phrases (entity_profile, recent_alerts), and domain-prefixed names (polymarket_edges, pipeworx_trending). It's readable but not a consistent pattern.

Tool Count2/5

At 33 tools the surface is large, with duplicated ask_pipeworx variants, a modest IP lookup core, and a large number of meta/management tools (memory, subscriptions, onboarding, feedback). Even with a broad scope this feels overloaded, and it is well above the 25+ threshold.

Completeness4/5

The query domain is well covered: entity profiles, comparison, claim validation, deep research, changes, plus memory and subscription management. Minor gaps exist (no direct subscription update, no raw citation fetch utility), but agents can work around them.